Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Thursday November 5, 2009

DrStockPick.com Stock Report!

**************************************************************

Cavitation Technologies, Inc. (OTC Bulletin Board: CVAT) announced recently that it has signed Miura Engineering Co., Ltd. Tokyo, Japan (www.miura21.co.jp) as its new agent to serve markets in Japan for CTI’s Nano-Cavitation Process Systems. Miura is a leading Engineering Company specialized in Edible Oil Processing Plants in the Far East. Last week CVAT reported a 3-for-1 forward stock split.

At the 2nd Asia Pacific Contact Center Association Leaders and CCAM Expo this week in Kuala Lumpur, Malaysia, Convergys

...

Geron Corporation (NASDAQ:GERN) today announced that they have reached an agreements with the Food and Drug Administration to re-initiate clinical trials for spinal cord injury. The company said that they plan to advance clinical development of their human embryonic stem cell (hESC)-based product, GRNOPC1 which will be used for the treatment of spinal cord injuries. The plan is to let Geron Corporation restart the Phase 1 clinical trial of GRNOPC1 in patients who are suffering from complete thoracic spinal cord injury and to support the future expansion of the clinical trial with patients who are suffering from cervical injuries.

Geron Corporation is one of the developers for the first-in-class biopharmaceuticals that is used for the treatment of cancer and chronic degenerative diseases like spinal cord injury, diabetes and heart failure. GRNOPC1 that is being developed by Geron Corporation is made for the treatment of spinal cord injury but Geron is

...

AVI BioPharma have recently announced that they have received a funding for expansion plans of their Junin virus drug treatment. Soon after the annoucement was made, AVI BioPharma stocks were trading higher on a surge in volume. AVI BioPharma has announced that they have received expanded contract of approximately US$ 11.5 million from the Defense Department that will help them support the development of their drug candidate named as AVI-7012 to treat Junin virus infection. The news made AVI BioPharma one of the NASDAQ’s top performers on Monday and the shares were rallying sharply higher on big volume.

AVI BioPharma shares were lately rising around 45 cents, or 28.9 percent, to $2.01. However, later in the day the share prices touched an intraday high of $2.08. More than 12 million shares

...

It was a downward slide for the Amicus Therapeutics on Monday when the drug company announced the failure of its drug candidate for Gaucher disease, an enzyme disorder. The shares of Amicus Therapeutics dropped considerably soon after the company came out with the disappointing news about the inefficiency of their drug named Plicera. The shares of Amicus dropped around $2.77, or 32.6 percent to $5.73 in the morning trading.

On Friday, Amicus Therapeutics came out with the news of the failure of their drug candidate Plicera and said that the drug did not appear to work for many patients in the midstage clinical trial as expected and so they had to come out with the sad news. Gaucher disease is an enzyme disorder that can harm the liver and cause neurological complications.

...

Swiss-based drug company Anavex Life Sciences Corp. announced today that they have selected FORENAP Pharma as the contract research organization for Phase 1 clinical trials of ANAVEX 2-73, the company’s lead Alzheimer’s drug candidate.

FORENAP has been involved in pre-clinical and clinical research for 20 years and is renowned for its expertise in central nervous system studies, including Alzheimer’s disease. FORENAP will perform study setup, protocol review, site monitoring and project management for the trials. Rudy Luthringer, CEO of FORENAP, said, “We look forward to running a high-quality and cost-effective program as Anavex works to confirm its pre-clinical findings in a clinical setting.”

ANAVEX 2-73 has been shown in pre-clinical testing to be neuroprotective and anti-amnesic. It is thought that the drug impacts mitochondrial dysfunction and it may be mitochondrial protective. Mitochondrial dysfunction is thought by many researchers to be one of the hallmarks of Alzheimer’s disease.

Avanex Life Sciences is approaching Alzheimer’s

...

DrStockPick.com Stock Report!

Tuesday September 15, 2009

**************************************************************

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon’s fourth drug candidate currently being tested in Phase 2 clinical trials.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT),

...

Anil Diwan, Ph.D., president of NanoViricides, Inc., a development stage company creating special purpose nanomaterials for viral therapy, revealed the remarkable potential of this new class of drugs for the treatment of viral disease in a presentation given at the 8th annual NanoBusiness Conference in Chicago recently.

NanoViricides has created a class of drug candidates, under the Nanoviricide™ name, that comes as close as anything to the sought after “magic bullet”, able to zero in on specific virus particles and dismantle them. The company is already developing drugs against a number of viral diseases, including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital herpes, and viral diseases of the eye. They are also working on drugs against Hepatitis C, Rabies, and the deadly Ebola virus, among others.

Dr. Diwan described the remarkable way the new drugs are able to focus in and destroy virus particles. “Viruses

...

Yesterday, ISTA Pharmaceuticals Inc. (ISTA) announced that the U.S. Food and Drug Administration (FDA) approved its drug candidate, Bepreve, for the treatment of ocular itching associated with allergic conjunctivitis in patients two years and above. The drug is approved as a twice-daily prescription eye drop treatment. ISTA filed the New Drug Application for the drug (bepotastine ophthalmic solution) on Nov 13, 2008.  As a reminder, the advisory committee of the FDA had recommended the drug in June. The seven-member panel had voted unanimously in favor of Bepreve after reviewing comprehensive safety and efficacy data from ISTA's clinical program.  Bepreve is expected to be available to ophthalmologists and patients in the United States in the fourth quarter of 2009. The company, which expects to recognize revenues from the drug from this year, is expanding its sales force for this purpose.  ISTA has three drugs on the ...

Veritec Moves from Pink Sheets to OTC Bulletin Board

-Veritec, Inc. (OTCBB:VRTC), a pioneer and developer of proprietary two-dimensional matrix technology and developer of mobile banking debit card solutions, today September 4, 2009 announced that its common stock has begun trading on the OTC Bulletin Board (OTCBB). Veritec’s common stock was previously quoted on the Pink Sheets.

“Veritec is very pleased to move from the Pink Sheets to the OTC Bulletin Board,” said Jeff Hattara, President and CEO of Veritec, Inc. “As reflected in our recent press releases, Veritec has had a number of significant commercial achievements in the last few months. We’ve taken this step to increase Veritec’s exposure to investors and improve liquidity in the trading of our common stock as part of our overall strategy to drive value for the company’s shareholders”.

About Veritec, Inc.

Veritec, Inc. is a pioneer and developer of proprietary two-dimensional matrix technology. The company’s portfolio

...

DrStockPick.com Stock Report!

Tuesday August 18, 2009

**************************************************************

Desert Equity LP, a Delaware limited partnership, today announced that it has commenced its previously announced cash tender offer for up to a total of 3,740,000 shares of common stock, or approximately 16.3% of the shares outstanding, of White Electronic Designs Corporation (Nasdaq: WEDC), at a price of $4.25 net per share in cash (subject to applicable withholding of U.S. federal, state and local taxes).

Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax’s 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under

...